(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.98%.
Janux Therapeutics's earnings in 2026 is -$102,592,000.On average, 21 Wall Street analysts forecast JANX's earnings for 2026 to be -$108,878,479, with the lowest JANX earnings forecast at -$137,203,146, and the highest JANX earnings forecast at -$64,963,935. On average, 19 Wall Street analysts forecast JANX's earnings for 2027 to be -$166,903,390, with the lowest JANX earnings forecast at -$202,509,447, and the highest JANX earnings forecast at -$132,238,840.
In 2028, JANX is forecast to generate -$206,721,771 in earnings, with the lowest earnings forecast at -$304,962,451 and the highest earnings forecast at -$143,151,754.